Eli Lilly's Alzheimer's Disease Medication Approved by FDA

A major rice pharmaceutical companyEli LillyAlzheimer's disease treatment drugs developed by have been approved in the United States. It received approval from the U.S. Food and Drug Administration (FDA) for the second time as a drug that delays the progression of symptoms in 6 million patients in the United States.

　　It was over 3 years ago that “donanemab AZBT (kisunla)” showed effects in clinical trials. The approval, which was obtained after numerous delays in regulatory procedures, was a big win for Lily and investors. Approved for sale in the US in early 2023EisaiIt competes with “Rekembi.”